1
|
Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival? Ann Surg Oncol 2020; 27:983. [PMID: 32699930 DOI: 10.1245/s10434-020-08871-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
C.R. Farley and M.C. Perez contributed equally to this publication and are co-first authors. J.S. Zager and M.C. Lowe contributed equally to this publication and are co-corresponding authors.
Collapse
Affiliation(s)
- C R Farley
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - M C Perez
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - S J Soelling
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - K A Delman
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA.,Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - A Harit
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - E J Wuthrick
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - J L Messina
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - V K Sondak
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - J S Zager
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
| | - M C Lowe
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
| |
Collapse
|
2
|
Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival? Ann Surg Oncol 2020; 27:1978-1985. [PMID: 32103415 DOI: 10.1245/s10434-019-08187-w] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Indexed: 11/18/2022]
Abstract
INTRODUCTION The eighth edition of the American Joint Committee on Cancer (AJCC8) Staging Manual provides important information for staging and prognostication; however, survival estimates for patients with Stage I-III Merkel cell carcinoma (MCC), a rare disease, may be as practical using data from large-volume centers as that collated for the AJCC analysis. As such, we compared our institutional outcomes to AJCC8. METHODS Patients who presented from 2005 to 2017 with MCC to two high-volume centers were included. Demographics, clinicopathologic characteristics, survival and recurrence data were compiled, and outcomes compared to AJCC8. RESULTS A total of 409 patients were included. Median age was 75 (range 29-98) years, and 68% were male. Median follow-up was 16 months (0-157). Five-year overall survival (OS) was 70%; 5-year disease-specific survival (DSS) was 84%. When stratified by extent of disease, 5-year OS was higher for patients with local disease compared to those with nodal disease (72.6% vs 62.7%, p=0.005). Similarly, patients with local disease had higher 5-year DSS than those with nodal disease (90.1% vs 76.8%, p=0.002). Five-year recurrence-free survival was 59.2% for all patients, 65.0% for local disease and 48.3% for nodal disease (p=0.033). CONCLUSIONS Here, MCC patients with local or nodal disease have substantially higher OS rates than predicted in AJCC8 (5-year: 72.6% vs 50.6%; 62.7% vs 35.4%, respectively). Importantly, 5-year DSS was significantly better than the OS rates reported presently and in AJCC8. As clinicians and patients rely on AJCC to accurately prognosticate and guide treatment decisions, these estimates should be reassessed and updated to more accurately predict survival outcomes.
Collapse
Affiliation(s)
- C R Farley
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
| | - M C Perez
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - S J Soelling
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| | - K A Delman
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA.,Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - A Harit
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - E J Wuthrick
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - J L Messina
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - V K Sondak
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - J S Zager
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | - M C Lowe
- Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA
| |
Collapse
|
3
|
Pingpank JF, Hughes MS, Alexander HR, Faries MB, Zager JS, Royal R, Whitman ED, Nutting CW, Siskin GP, Agarwala SS. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.18_suppl.lba8512] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA8512 Background: Patients with hepatic metastases from primary melanoma have a median survival between 6 and 9 months. Few treatment strategies provide a meaningful impact on outcome. This report examines the efficacy of a minimally invasive regional therapy with melphalan (MEL) in patients with hepatic metastases from malignant melanoma. Methods: Between February 2006 and October 2009, 93 patients (M:F; 45:48) were accrued to a phase III, random-assignment trial comparing percutaneous hepatic perfusion (PHP-mel) (n=44) to standard of care (BAC) (n=49). This represents 100% of a planned 92 patient accrual. The primary endpoint was hepatic progression-free survival (H-PFS). Crossover to PHP-mel therapy was permitted at hepatic progression. Secondary endpoints included assessment of response rate (RR), duration of response (RES), and overall survival (OS) after PHP. A planned PHP treatment regimen included 4 to 6 PHP procedures at 28 to 35 day intervals. MEL (3.0 mg/kg) was delivered via the hepatic artery in a 30-minute hepatic artery infusion via a percutaneously placed catheter with hepatic venous hemofiltration using a retrohepatic, double balloon catheter (Delcath Systems, Inc.) and paired hemofiltration cartridges. Patients randomized to BAC were offered treatment considered to be the best alternative regimen by the treating physician. Staging evaluations were performed at baseline and then at 6 to 8 week intervals post baseline. All responses represent investigator-based results and were evaluated via standard RECIST criteria. Intent to treat based survival analysis was via the Kaplan-Meier method, with a 2-sided p< 0.05 defining significance. Results: Median H-PFS was 245 days (CI:136, 267) for PHP-mel vs. 49 days (CI:43, 68) for BAC (p<0.001). Overall response rate was 34.1 % (15/44) (CI: 20.5, 49.9) for PHP (15/44) vs. 2.0 % (1/49) (CI: 0.1, 10.9) for BAC (p<0.001). Upon hepatic progression, crossover to PHP occurred in 27 patients (55%) randomized to BAC. Conclusions: For patients with metastatic melanoma to the liver, H-PFS is significantly improved with PHP-mel versus best available care. [Table: see text]
Collapse
Affiliation(s)
- J. F. Pingpank
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - M. S. Hughes
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - H. R. Alexander
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - M. B. Faries
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - J. S. Zager
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - R. Royal
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - E. D. Whitman
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - C. W. Nutting
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - G. P. Siskin
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| | - S. S. Agarwala
- University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA; Surgery Branch, National Cancer Institute, Bethesda, MD; University of Maryland School of Medicine, Baltimore, MD; John Wayne Cancer Institute, Santa Monica, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Texas M. D. Anderson Cancer Center, Houston, TX; Atlantic Melanoma Center, Morristown, NJ; Radiology Imaging Associates, Englewood, CO; Albany Medical Center Hospital, Albany, NY; St. Luke's Hospital and
| |
Collapse
|
4
|
Beasley G, Sanders G, Zager JS, Hochwald SN, Grobmyer S, Andtbacka RH, Peterson B, Peters WP, Ross MI, Tyler DS. A prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion (M-ILI) in patients with advanced extremity melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9025^ Background: ILI with melphalan dosing corrected for ideal body weight (IBW) is a well tolerated treatment for patients with in-transit extremity melanoma with an approximate 30% CR and 44% overall response rate. ADH-1 is a cyclic pentapeptide that disrupts N-cadherin adhesion complexes. ADH-1 when given systemically in a preclinical model with regional melphalan demonstrated synergistic antitumor activity and had minimal toxicity in a Phase I trial with M-ILI. Methods:AJCC stage IIIB or IIIC extremity melanoma patients were treated with 4000mg of ADH-1 administered systemically on Day 1 and 8 in addition to standard dose M-ILI corrected for IBW on Day 1. Drug pK, and N-cadherin IHC staining were performed on pretreatment tumor from all patients. The primary endpoint was response at 12 weeks determined by modified RECIST. Results: 46 patients were enrolled over 15 months at 4 institutions. Thirty-four patients are presently evaluable for 12 week response. In field responses include 14 CRs (41.2%%), 9 PRs (26.5%), 5 SDs (14.7%), and 6 PDs (17.6%). The OR rate was 67.7% and at a median follow-up of 30 weeks, 8 patients have sustained CRs over 6 months. Of 34 patients, 9 have developed disease outside the region of infusion (median time to progression 12 weeks) at median follow-up 36 weeks. N-cadherin was detected in 20 of 25 (80%) pretreatment tumor samples. Grade IV toxicities included CPK elevation (4), neutropenia (1), acute respiratory distress syndrome (1), pneumonitis (1), and pulmonary infiltrate (1). There were no limb losses or compartment syndromes. Conclusions:This study is not only the first prospective multi-center ILI trial but also the first ILI study to incorporate a targeted agent in an attempt to augment anti-tumor responses. The treatment was well tolerated with CR and OR rates that appear to be significantly improved from standard M-ILI alone. Targeting N-cadherin may represent a novel strategy for improving melanoma sensitivity to chemotherapeutic agents and warrants further investigation in a large randomized multi-center trial. [Table: see text] ASCO Conflict of Interest Policy and Exceptions In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2009 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest .
Collapse
Affiliation(s)
- G. Beasley
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - G. Sanders
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - J. S. Zager
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - S. N. Hochwald
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - S. Grobmyer
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - R. H. Andtbacka
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - B. Peterson
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - W. P. Peters
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - M. I. Ross
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| | - D. S. Tyler
- Duke University, Durham, NC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; University of Florida, Gainesville, FL; University of Utah, Salt Lake City, UT; Adherex Technologies, Inc., Durham, NC; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
5
|
Averbook BJ, Jukic D, Rao JS, Panneerselvam A, Delman K, Zager JS, Sabel M, Pittelkow MR, Swetter S, Kirkwood JM. First analysis of an international pediatric melanoma and atypical melanocytic neoplasm database. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9013 Background: Pediatric melanoma (PM) care has been extrapolated from adult melanoma data. PM and atypical melanocytic neoplasms (AMNs) appear to have different biology. An international database (DB) was developed to clarify their behavior. Methods: IRB approval was obtained at 12 institutions. An SQL-DB was developed for web entry of de-identified demographic and pathologic data for PM and AMN patients (pts) < 21yr through an honest broker system at the University of Pittsburgh. Institutions retained a key of pts entered with assigned numbers for quality assurance and updates. Statistical analysis used Kaplan-Meier survival curves, univariate linear trends and log rank tests. In situ melanoma was excluded from PM survival analysis. Results: 828 pts were registered as of 31 Oct 2008 (ages 11mo-23; median 15yr). 34 pts 21–23yr entered were left in the DB for statistical comparison. Diagnosis years ranged from 1936–2008. 455 pts had complete follow-up. Too few AMN pts had complete follow-up for analysis (18/208). After excluding 32 in situ and 40 with other incomplete data, 365 PM out of 415 total PM were evaluable for OS and 351 for DFS (Stage IV removed). Mean/median age for evaluable PM pts was 16.44/17-yrs (range 1–21yr). 591 pts were age 10–20 while 203 were < 10. Sentinel lymph node (SLN) biopsy showed spread in 30.1 % PM pts (compared to 50% [4/8] of AMN SLN pts). 10-yr PM OS was 80.6%, and pts 0–10 yr had 100% 10-yr OS compared to 69.6% for pts age 10–15 and 79.49% for age 15–20 (p= 0.1473). OS did not differ significantly by gender. Stage predicted OS (p<0.0001). 10-yr OS was 94.13% for Stage I (n=174), 79.62% for stage II (n=67) & 77.14% for stage III (n=75). Thickness affected 10-yr OS: 0–1mm=97% (n=147), 1.1–2mm 70% (n=84), 2.01–4mm 78% (n=71) & >4mm 81% (n=25), p= 0.0099. Survival was similar for pts with PM > 1mm of the several T stage groupings. Ulceration adversely affected OS (p=0.022). Mitosis, defined as present/absent did not alter survival. Nodal metastasis correlated with worse OS (p= 0.170). Conclusions: Stage, thickness, ulceration, and nodal status are significant predictors of OS for PM. Further study will focus on multivariable analysis of PM and AMNs after updating pts, increasing accrual, and cleaning data. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. J. Averbook
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - D. Jukic
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - J. S. Rao
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - A. Panneerselvam
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - K. Delman
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - J. S. Zager
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - M. Sabel
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - M. R. Pittelkow
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - S. Swetter
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| | - J. M. Kirkwood
- Metrohealth Medical Center/CWRU, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Emory University, Atlanta, GA; H. Lee Moffitt Cancer Center, Tampa, FL; University of Michigan, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Stanford University/VA Palo Alto, Stanford, CA
| |
Collapse
|
6
|
Lin YG, Deavers M, Sasan F, Zager JS, Ramondetta LM. Clinical challenges presented by three simultaneous solid tumors. Gynecol Oncol 2006; 103:1159-63. [PMID: 17055558 DOI: 10.1016/j.ygyno.2006.08.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 07/28/2006] [Accepted: 08/06/2006] [Indexed: 11/20/2022]
Abstract
BACKGROUND Simultaneous tumors are rare, and their management can be challenging. The simultaneous presentation of cervical carcinoma, renal cell carcinoma, and appendiceal carcinoma has not been previously described. CASE A 57-year-old woman presented with cervical cancer. During her workup, she was diagnosed with mucinous appendiceal carcinoma and clear cell carcinoma of the kidney. One year following surgery, she remains without evidence of disease and with continually improving nutritional status. CONCLUSION When simultaneous tumors are diagnosed, optimal care requires the creative expertise of a multidisciplinary team. Standard sequential therapies may be problematic in patients undergoing major surgery to treat another primary tumor, and sequential treatment delays rather than combining therapies can jeopardize cure. Treatment planning should utilize a coordinated multidisciplinary approach.
Collapse
MESH Headings
- Adenocarcinoma, Clear Cell/diagnosis
- Adenocarcinoma, Clear Cell/pathology
- Adenocarcinoma, Clear Cell/therapy
- Adenocarcinoma, Mucinous/diagnosis
- Adenocarcinoma, Mucinous/pathology
- Adenocarcinoma, Mucinous/therapy
- Appendiceal Neoplasms/diagnosis
- Appendiceal Neoplasms/pathology
- Appendiceal Neoplasms/therapy
- Carcinoma, Squamous Cell/diagnosis
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/therapy
- Combined Modality Therapy
- Diagnosis, Differential
- Female
- Humans
- Kidney Neoplasms/diagnosis
- Kidney Neoplasms/pathology
- Kidney Neoplasms/therapy
- Middle Aged
- Neoplasm Staging
- Neoplasms, Multiple Primary/diagnosis
- Neoplasms, Multiple Primary/diagnostic imaging
- Neoplasms, Multiple Primary/pathology
- Neoplasms, Multiple Primary/therapy
- Radiography
- Uterine Cervical Neoplasms/diagnosis
- Uterine Cervical Neoplasms/pathology
- Uterine Cervical Neoplasms/therapy
Collapse
Affiliation(s)
- Y G Lin
- Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Division of Gynecologic Oncology, Lyndon Baines Johnson General Hospital, Houston, TX 77230-1439, USA
| | | | | | | | | |
Collapse
|
7
|
Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther 2006; 13:326-34. [PMID: 16138120 DOI: 10.1038/sj.cgt.7700890] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Replication-competent oncolytic herpes simplex viruses (HSV), modified by deletion of certain viral growth genes, can selectively target malignant cells. The viral growth gene gamma(1)34.5 has significant homology to GADD34 (growth arrest and DNA damage protein 34), which promotes cell cycle arrest and DNA repair in response to stressors such as radiation (XRT). By upregulating GADD34, XRT may result in greater oncolytic activity of HSV strains deficient in the gamma(1)34.5 gene. The human cholangiocarcinoma cell lines KMBC, SK-ChA-1 and YoMi were treated with NV1023, an oncolytic HSV lacking one copy of gamma(1)34.5. Viral proliferation assays were performed at a multiplicity of infection (MOI, number of viral particles per tumor cell) equal to 1, either alone or after XRT at 250 or 500 cGy. Viral replication was assessed by plaque assay. In vitro cytotoxicity assays were performed using virus at MOIs of 0.01 and 0.1, with or without XRT at 250 cGy and cell survival determined with lactate dehydrogenase assay. Established flank tumors in athymic mice were treated with a single intratumoral injection of virus (10(3) or 10(4) plaque forming units), either alone or after a single dose of XRT at 500 cGy, and tumor volumes measured. RT-PCR was used to measure GADD34 mRNA levels in all cell lines after a single dose of XRT at 250 or 500 cGy. NV1023 was tumoricidal in all three cell lines, but sensitivity to the virus varied. XRT enhanced viral replication in vitro in all cell lines. Combination treatment with low-dose XRT and virus was highly tumoricidal, both in vitro and in vivo. The greatest tumor volume reduction with combination therapy was seen with YoMi cells, the only cell line with increased GADD34 expression after XRT and the only cell line in which a synergistic treatment effect was suggested. In KMBC and SK-ChA-1 cells, neither of which showed increased GADD34 expression after XRT, tumor volume reduction was less pronounced and there was no suggestion of a synergistic effect in either case. Oncolytic HSV are effective in treating human cholangiocarcinoma cell lines, although sensitivity to virus varies. XRT-enhanced viral replication occurs through a mechanism that is not necessarily dependent on GADD34 upregulation. However, XRT-induced upregulation of GADD34 further promotes tumoricidal activity in viral strains deficient in the gamma(1)34.5 gene, resulting in treatment synergy; this effect is cell type dependent. Combined XRT and oncolytic viral therapy is a potentially important treatment strategy that may enhance the therapeutic ratios of both individual therapies.
Collapse
Affiliation(s)
- W R Jarnagin
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Zager JS, Delman KA, Ebright MI, Malhotra S, Larson S, Fong Y. Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver. Br J Surg 2003; 90:1225-31. [PMID: 14515291 DOI: 10.1002/bjs.4207] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
BACKGROUND The aim of the study was to determine whether hepatic regeneration stimulates growth of tumour residing within the liver, and whether a difference in the rate of DNA synthesis in liver and tumour may be used to target cancer using the radiolabelled thymidine analogue 5-iodo-2'-deoxyuridine (IUdR). METHODS Partial hepatectomy was performed on Buffalo rats bearing solitary nodules of syngeneic Morris hepatoma. Liver and tumour DNA synthesis was measured by incorporation of radioactive IUdR. [(125)I]IUdR was tested as an adjuvant therapy after hepatectomy in Buffalo rats bearing diffuse microscopic Morris hepatomas to simulate the clinical situation. RESULTS Liver regeneration enhanced liver and tumour DNA synthesis as measured by incorporation of radioactive IUdR. Liver DNA synthesis returned to baseline by 7 days, whereas tumour DNA synthesis remained above baseline level. Hepatectomy enhanced the growth of microscopic liver tumours. [(125)I]IUdR (250 micro Ci or 1 mCi/kg) administered 4 days after hepatectomy significantly reduced tumour growth without signs of systemic toxicity or liver dysfunction. CONCLUSION The local environment of the regenerating liver stimulates tumour growth. The thymidine analogue [(125)I]IUdR may be used preferentially to target tumour DNA synthesis in the regenerating liver, and may prove useful as an adjuvant therapy for hepatic tumours after surgical resection.
Collapse
Affiliation(s)
- J S Zager
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
| | | | | | | | | | | |
Collapse
|
9
|
Jarnagin WR, Zager JS, Klimstra D, Delman KA, Malhotra S, Ebright M, Little S, DeRubertis B, Stanziale SF, Hezel M, Federoff H, Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003; 10:215-23. [PMID: 12637943 DOI: 10.1038/sj.cgt.7700558] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The objective of the study was to evaluate the utility of NV1042, a replication competent, oncolytic herpes simplex virus (HSV) containing the interleukin-12 (IL-12) gene, as primary treatment for hepatic tumors and to further assess its ability to reduce tumor recurrence following resection. Resection is the most effective therapy for hepatic malignancies, but is not possible in the majority of the patients. Furthermore, recurrence is common after resection, most often in the remnant liver and likely because of microscopic residual disease in the setting of postoperative host cellular immune dysfunction. We hypothesize that, unlike other gene transfer approaches, direct injection of liver tumors with replication competent, oncolytic HSV expressing IL-12 will not only provide effective control of the parent tumor, but will also elicit an immune response directed at residual tumor cells, thus decreasing the risk of cancer recurrence after resection. Solitary Morris hepatomas, established in Buffalo rat livers, were injected directly with 10(7) particles of NV1042, NV1023, an oncolytic HSV identical to NV1042 but without the IL-12 gene, or with saline. Following tumor injection, the parent tumors were resected and measured and the animals were challenged with an intraportal injection of 10(5) tumor cells, recreating the clinical scenario of residual microscopic cancer. In vitro cytotoxicity against Morris hepatoma cells was similar for both viruses at a multiplicity of infection of 1 (MOI, ratio of viral particles to target cells), with >90% tumor cell kill by day 6. NV1042 induced high-level expression of IL-12 in vitro, peaking after 4 days in culture. Furthermore, a single intratumoral injection of NV1042, but not NV1023, induced marked IL-12 and interferon-gamma (IFN-gamma) expression. Both viruses induced a significant local immune response as evidenced by an increase in the number of intratumoral CD4(+) and CD8(+) lymphocytes, although the peak of CD8(+) infiltration was later with NV1042 compared with NV1023. NV1042 and NV1023 reduced parent tumor volume by 74% (P<.003) and 52% (P<.03), respectively, compared to control animals. Treatment of established tumors with NV1042, but not with NV1023, significantly reduced the number of hepatic tumors after resection of the parent tumor and rechallenge (16.8+/-11 (median=4) vs. 65.9+/-15 (median=66) in control animals, P<.025). In conclusion, oncolytic HSV therapy combined with local immune stimulation with IL-12 offers effective control of parent hepatic tumors and also protects against microscopic residual disease after resection. The ease of use of this combined modality approach, which appears to be superior to either approach alone, suggests that it may have clinical relevance, both as primary treatment for patients with unresectable tumors and also as a neoadjuvant strategy for reducing recurrence after resection.
Collapse
Affiliation(s)
- W R Jarnagin
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Zager JS, Delman KA, Malhotra S, Ebright MI, Bennett JJ, Kates T, Halterman M, Federoff H, Fong Y. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med 2001; 7:561-8. [PMID: 11591892 PMCID: PMC1950059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
BACKGROUND Herpes simplex type I (HSV)-based vectors have been used experimentally for suicide gene therapy, immunomodulatory gene delivery, and direct oncolytic therapy. The current study utilizes the novel concept of regional delivery of an oncolytic virus in combination with or serving as the helper virus for packaging herpes-based amplicon vectors carrying a cytokine transgene, with the goal of identifying if this combination is more efficacious than either modality alone. MATERIALS AND METHODS A replication competent oncolytic HSV (G207) and a replication incompetent HSV amplicon carrying the gene for the immunomodulatory cytokine IL-2 (HSV-IL2) were tested in murine syngeneic colorectal carcinoma and in rat hepatocellular carcinoma models. Liver tumors were treated with vascular delivery of (1) phosphate-buffered saline (PBS), (2) G207, (3) HSV-IL2, (4) G207 and HSV-IL2 mixed in combination (mG207/HSV- IL2), and (5) G207 as the helper virus for packaging the construct HSV-IL2 (pG207/HSV-IL2). RESULTS Tumor burden was significantly reduced in all treatment groups in both rats and mice treated with high-dose G207, HSV-IL2, or both (p < 0.02). When a low dose of virus was used in mice, anti-tumor efficacy was improved by use of G207 and HSV-IL2 in combination or with HSV-IL2 packaged by G207 (p < 0.001). This improvement was abolished when CD4(+) and CD8(+) lymphocytes were depleted, implying that the enhanced anti-tumor response to low-dose combined therapy is immune mediated. CONCLUSIONS Vascular regional delivery of oncolytic and amplicon HSV vectors can be used to induce improved anti-tumor efficacy by combining oncolytic and immunostimulatory strategies.
Collapse
Affiliation(s)
- J S Zager
- Department of Surgery, Hepatobiliary Division, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Zager JS, Gusani NJ, Derubertis BG, Shaw JP, Kaufman JP, DeNoto G. Laparoscopic appendectomy for Crohn's disease of the appendix presenting as acute appendicitis. J Laparoendosc Adv Surg Tech A 2001; 11:255-8. [PMID: 11569518 DOI: 10.1089/109264201750539808] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Crohn's disease confined to the appendix is rare but has been well described in the literature. It can mimic acute appendicitis clinically. After surgical treatment, recurrences of Crohn's disease are rare. We report the first case of treatment by laparoscopic appendectomy of Crohn's disease confined to the appendix. METHODS A healthy 32-year old man presented with a week-long history of vague lower abdominal pain. Diagnostic work-up, which included CT, enteroclysis, and routine blood work, revealed a patent appendiceal lumen with an inflammatory mass in the right lower quadrant. RESULTS Diagnostic laparoscopy revealed an inflamed appendix, and a laparoscopic appendectomy was performed, with frozen-section examination revealing Crohn's disease of the appendix. Two years after surgery, the patient has not had a recurrence of symptoms. CONCLUSIONS Crohn's disease of the appendix can mimic acute appendicitis, although often with a more indolent course. The disease may be treated successfully by laparoscopic appendectomy, with good long-term results.
Collapse
Affiliation(s)
- J S Zager
- Department of Surgery. North Shore University Hospital, New York University School of Medicine, Manhasset, USA.
| | | | | | | | | | | |
Collapse
|
12
|
Abstract
BACKGROUND/AIMS Jejunal diverticulosis (JD) is a rare disease that has a variable presentation. The signs, symptoms, diagnosis, complications and treatment of JD will be discussed through a review of the literature and a series of cases from our own institution. METHODS A retrospective analysis of the diagnosis, treatment and complications of JD was performed by a literature review. This was accompanied by a series of four cases of JD diagnosed and treated in our own institution. CONCLUSIONS JD is a rare disease in which most patients are asymptomatic. However, JD's different complications are serious and can be fatal. The treatment is mainly surgical; however, there have been cases where nonsurgical management was successful.
Collapse
Affiliation(s)
- J S Zager
- Department of Surgery, North Shore University Hospital, New York University School of Medicine, Manhasset, N.Y., USA.
| | | | | | | | | |
Collapse
|
13
|
Abstract
BACKGROUND/AIMS Inflammatory fibrous polyps (IFPs), also known as inflammatory pseudotumors, occur rarely in the gastrointestinal tract. IFPs have variable presentations, often presenting as small bowel obstruction due to intussusception or, less commonly, as an incidental finding on radiological examinations or screening colonoscopies. The diagnosis and management of IFPs will be discussed through a review of the literature and a series of cases from our own institution. METHODS A retrospective analysis of the diagnosis, management and complications of IFPs was performed by a literature review. This was accompanied by a series of 3 cases of IFPs, 2 of which causing intussusception, diagnosed and treated in our own institution. CONCLUSIONS IFP is a rare disease and has a variable presentation, from asymptomatic to small bowel obstruction due to intussusception. IFPs cannot be differentiated from malignancy without histological examination. Therefore, whether diagnosed incidentally or in the setting of intussusception, the treatment of IFPs is surgical resection of the involved bowel.
Collapse
Affiliation(s)
- J S Zager
- Department of Surgery, North Shore University Hospital, New York University School of Medicine, Manhasset, N.Y, USA.
| | | | | | | |
Collapse
|
14
|
Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H, Kooby DA, Hawkins WG, Horsburgh BC, Johnson P, Fong Y. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000; 11:2465-72. [PMID: 11119418 DOI: 10.1089/10430340050207957] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Abstract
Herpes simplex viruses (HSV) type 1 are the basis of a number of anticancer strategies that have proven efficacious in animal models. They are natural human pathogens and the majority of adults have anti-HSV immunity. The current study examined the effect of preexisting immunity on the response to herpes-based oncolytic viral treatment of hepatic metastatic cancer in a murine model designed to simulate a clinical approach likely to be utilized for nonneurological tumors. Specifically, the anticancer effects of NV1020 or G207, two multimutated HSV-1 oncolytic viruses, were tested in immunocompetent mice previously immunized with a wild-type herpes simplex type 1 virus. Mice were documented to have humoral as well as cell-mediated immunity to HSV-1. Tumor response to oncolytic therapy was not measurably abrogated by immunity to HSV at the doses tested. The influence of route of viral administration was also tested in models of regional hepatic arterial and intravenous therapy. Route of viral administration influenced efficacy, as virus delivered intravenously produced some detectable attenuation while hepatic arterial therapy remained unaffected. These results demonstrate that when given at appropriate doses and in reasonable proximity to tumor targets, HSV-based oncolytic therapy can still be expected to be effective treatment for patients with hepatic malignancies.
Collapse
Affiliation(s)
- K A Delman
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
Granular cell tumors are rare, invariably benign, and often solitary tumors, which infrequently involve the gastrointestinal tract. We report the unique presentation of a granular cell tumor of the internal anal sphincter in a 75 year-old female. The tumor was detected during investigation of new rectal bleeding and was excised using a transanal approach and sphincter repair. At five-year follow-up the patient reported normal continence to stool and flatus and demonstrated no evidence of tumor recurrence. Immunohistochemical studies cite the Schwann neural cell as the origin of the granular cell tumor. Cytoplasmic features include acidophilic, p-aminosalicylic acid-positive, diastaseresistant granules. Granular cell tumors may be located anywhere in the body, but anorectal involvement is rare. In our own search of the world literature, no other cases were reported specifically to involve the anal sphincter. Granular cell tumors are usually detected incidentally but may be symptomatic, especially when the anorectal region is involved. Symptoms include perianal discomfort and bleeding. Adequate local excision is effective for both diagnosis and treatment of anorectal granular cell tumors. Careful follow-up should be performed after excision because of the risk of recurrence.
Collapse
Affiliation(s)
- M G Cohen
- Division of Colon and Rectal Surgery, North Shore University Hospital, New York University School of Medicine, Great Neck, USA
| | | | | | | |
Collapse
|